Page 340 - Read Online

Page 12 of 14 Choi et al. Neuroimmunol Neuroinflammation 2018;5:42 I http://dx.doi.org/10.20517/2347-8659.2018.47

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther
2015;37:764-82.
2. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin
Oncol 2017;14:463-82.
3. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer
therapy. Nat Rev Cancer 2016;16:275-87.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in
cancer. N Engl J Med 2012;366:2443-54.
5. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol
2015;42:587-600.
6. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018;15:422-42.
7. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, et al. European association for neuro-oncology (EANO) guideline on the
diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:e315-29.
8. Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of
nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 2017;19:iii21.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352:987-96.
10. Li B, Severson E, Pignon JC, Zhao H, Li T, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Genome Biol 2016;17:174.
11. Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, et al. T-cell exhaustion signatures vary with tumor type and are
severe in glioblastoma. Clin Cancer Res 2018;24:4175-86.
12. Chen Z, Hambardzumyan D. Immune microenvironment in glioblastoma subtypes. Front Immunol 2018;9:1004.
13. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol 2018;18:225-42.
14. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, et al. Gliomas promote immunosuppression through induction of B7-H1
expression in tumor-associated macrophages. Clin Cancer Res 2013; doi: 10.1158/1078-0432.CCR-12-3314.
15. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108-19.
16. Mallat M, Marín-Teva JL, Chéret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol
2005;15:101-7.
17. Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, et al. Glioma-associated microglia/macrophages display an expression profile
different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One 2015; doi: 10.1371/journal.pone.0116644.
18. Satoh J. Gene expression profiles of M1 and M2 microglia characterized by comparative analysis of public datasets. Clin Exp
Neuroimmunol 2018;9:124-38.
19. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, et al. Fate mapping analysis reveals that adult microglia derive from primitive
macrophages. Science 2010;330:841-5.
20. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function
throughout adult life. Nat Neurosci 2007;10:1538-43.
21. Tay TL, Mai D, Dautzenberg J, Fernández-Klett F, Lin G, et al. A new fate mapping system reveals context-dependent random or clonal
expansion of microglia. Nat Neurosci 2017;20:793-803.
22. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat
Neurosci 2016;19:20-7.
23. Ling EA. Some aspects of amoeboid microglia in the corpus callosum and neighbouring regions of neonatal rats. J Anat 1976;121:29-
45.
24. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci 2013;7:45.
25. Wolf SA, Boddeke HW, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol 2017;79:619-43.
26. Sobaniec-Lotowska ME. A transmission electron microscopic study of microglia/macrophages in the hippocampal cortex and neocortex
following chronic exposure to valproate. Int J Exp Pathol 2005;86:91-6.
27. Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology
2016;36:39-49.
28. Lou N, Takano T, Pei Y, Xavier AL, Goldman SA, et al. Purinergic receptor P2RY12-dependent microglial closure of the injured blood-
brain barrier. Proc Natl Acad Sci U S A 2016;113:1074-9.
29. Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, et al. Sall1 is a transcriptional regulator defining microglia identity and
function. Nat Immunol 2016;17:1397-406.
30. Prinz M, Erny D, Hagemeyer N. Ontogeny and homeostasis of CNS myeloid cells. Nat Immunol 2017;18:385-92.
31. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, et al. Environment drives selection and function of enhancers